paediatricsatic and geriatrics
Difference
paediatricsatic and geriatrics Difference
| Feature | Paediatrics | Geriatrics |
|---|---|---|
| Population | Children from birth to ~18 years | Adults typically ≥65 years (often ≥75 for geriatric syndromes) |
| Core process | Growth, development, maturation | Ageing, functional decline, frailty |
| Sub-groups | Neonates, infants, toddlers, school-age, adolescents | Young-old (65-74), old (75-84), oldest-old (≥85) |
| Drug | Concern |
|---|---|
| Codeine | CYP2D6 ultrarapid metabolism - fatal morphine toxicity; NOT recommended in paediatrics |
| Aspirin | Reye syndrome during viral illness |
| Doxycycline | Permanent tooth discoloration |
| Ceftriaxone | Kernicterus in neonates <28 days |
| Phenothiazines | Apnea/severe respiratory depression |
| TMP-SMX | Bilirubin displacement, kernicterus in <2 months |
| Paediatrics | Geriatrics | |
|---|---|---|
| Growth monitoring | Weight, height, head circumference centiles | Not applicable |
| Developmental milestones | Motor, speech, cognitive, social milestones | Not applicable |
| Functional assessment | School performance, play | ADLs/IADLs, gait speed, cognition (MMSE/MoCA) |
| Screening tools | Denver Developmental Screening | Geriatric Assessment - frailty, falls risk, polypharmacy review |
| Family involvement | Parental consent/history critical | Caregiver burden, advance care planning |
| Dimension | Paediatrics | Geriatrics |
|---|---|---|
| Trajectory | Upward (growth, gaining function) | Downward (decline, losing function) |
| Goal | Normal development and disease prevention | Maintaining independence, quality of life, preventing decline |
| Consent | Parental/guardian (child assents when able) | Patient (with capacity assessment; proxy if needed) |
| Drug labelling gaps | Most drugs studied in adults; paediatric data often missing | Elderly often excluded from trials; evidence gaps common |
| End-of-life | Rare (terminal illness in childhood) | Central concern; advance directives, palliative care |
For 2 marks viva
| Feature | Paediatrics | Geriatrics |
|---|---|---|
| Age group | Birth to 18 years | 65 years and above |
| Physiological process | Growth & development (immature organs) | Ageing & decline (degenerating organs) |
| Pharmacokinetics | Immature liver/kidney - slower drug metabolism | Reduced renal/hepatic clearance - drug accumulation |
| Drug dosing | Weight-based (mg/kg) | Reduced doses due to organ decline |
| Disease pattern | Congenital, infectious, developmental | Chronic, degenerative, multimorbidity |
| Polypharmacy | Uncommon | Very common |
| Consent | Parent/guardian gives consent | Patient gives consent (capacity assessed) |
| Goal | Achieve normal growth & development | Maintain independence & quality of life |
Paediatrics deals with growing, immature organ systems in children requiring weight-based dosing, while geriatrics deals with declining, degenerated organ systems in the elderly requiring dose reduction and polypharmacy management.
Brest feeding which drug decrease it
| Drug | Use |
|---|---|
| Bromocriptine | Classic drug to suppress lactation (inhibits prolactin directly) |
| Cabergoline | More potent, longer-acting; preferred over bromocriptine |
| Levodopa | Increases dopamine, reduces prolactin |
"Dopamine agonists such as bromocriptine inhibit prolactin secretion" - Costanzo Physiology, 7th Ed.
| Drug/Group | Mechanism |
|---|---|
| Bromocriptine / Cabergoline | Dopamine agonist → ↓ Prolactin |
| Estrogens (high dose) | Direct suppression of milk secretion |
| Pseudoephedrine | Vasoconstriction + glandular suppression |
| Furosemide | Fluid depletion |
| Alcohol (excess) | ↓ Oxytocin → impairs let-down |
| Stimulate Prolactin (↑ milk) | Inhibit Prolactin (↓ milk) |
|---|---|
| Pregnancy, breastfeeding | Dopamine |
| Sleep, stress | Bromocriptine (dopamine agonist) |
| TRH | Somatostatin |
| Dopamine antagonists | Prolactin itself (negative feedback) |
Dopamine agonists (bromocriptine, cabergoline) are the main drugs that decrease breastfeeding by inhibiting prolactin secretion from the anterior pituitary.
Laction period contraindication drug
| Category | Drugs |
|---|---|
| Breastfeeding CONTRAINDICATED | Anticancer drugs, Radioactive substances, Amphetamines, Ergotamines, Statins, Nitrofurantoin (in infants <1 month or with G6PD deficiency) |
| Avoid unless absolutely necessary | Chloramphenicol, Tetracyclines, Fluoroquinolones |
| Monitor infant for drowsiness | Psychiatric drugs (benzodiazepines, antipsychotics), Anticonvulsants |
| Monitor infant for jaundice | Sulfonamides, Dapsone, Mefloquine, Fansidar |
| May inhibit lactation | Estrogens, Thiazides |
| Drug | Reason |
|---|---|
| Cytotoxic/Anticancer drugs (methotrexate, cyclophosphamide) | Immunosuppression, bone marrow suppression in infant |
| Radioactive iodine (I-131) | Thyroid ablation in infant |
| Bromocriptine / Cabergoline | Suppresses lactation (stops milk) |
| Amphetamines | CNS stimulation, poor feeding in infant |
| Ergotamine | Vomiting, diarrhoea, convulsions in infant |
| Statins (atorvastatin, rosuvastatin) | Risk of disrupting infant lipid metabolism |
| Cocaine, heroin | Infant addiction, CNS toxicity |
| Drug | Reason |
|---|---|
| Chloramphenicol | Grey baby syndrome, bone marrow toxicity |
| Tetracyclines | Tooth discoloration, bone growth inhibition |
| Fluoroquinolones (ciprofloxacin) | Cartilage damage in infant joints |
| Methotrexate | Folate antagonism, immunosuppression |
| Lithium | Infant toxicity - cyanosis, hypotonia |
| Iodine-containing drugs (amiodarone) | Infant hypothyroidism |
| Drug | Effect to Watch |
|---|---|
| Benzodiazepines | Infant sedation, respiratory depression |
| Antipsychotics (haloperidol, clozapine) | Drowsiness, developmental effects |
| Phenobarbitone, phenytoin | Sedation, poor suckling |
| Sulfonamides, Dapsone | Haemolysis, jaundice (esp. G6PD deficiency) |
| Aspirin (high dose) | Reye syndrome, platelet dysfunction |
| Codeine | Morphine toxicity in ultra-rapid metabolisers |
Drugs absolutely contraindicated in lactation include anticancer drugs, radioactive iodine, amphetamines, ergotamines, statins, and chloramphenicol - they either harm the infant directly or suppress milk production.